Read More

Disney, Amgen, First Republic, Psychedelics: How One CEO’s Universal Deal-Making Approach Shapes Industries

In the dynamic world of business, adaptability is king, a principle veteran executive Richard Nanula has embodied throughout his career. "Every place I've been... maybe you could conclude that they might not fit because one of them didn't have much relation to the other.

KTTA

Read More

DMT’s Clinical Path For Treating TBI And Stroke: Phase 1 Dosing Finished As Phase 2 Gears Up

Algernon Pharmaceuticals’ (OTCQB: AGNPF) wholly-owned Algernon NeuroScience (AGN Neuro) successfully completed dosing the third and final cohort of its Phase 1 clinical study assessing an intravenous (IV) formulation of the company’s DMT compound, AP-188, aiming to treat both stroke and Traumati

AGNPF